Welichem Biotech Inc.

Corporate Profile Management Team Board of Directors Scientific & Medical Advisors Intellectual Property

WBI-1001 WBI-2100 Symbiochem

Investor Overview Financial Statements Sedar Filing

Press Releases Media Kit

Corporate Profile

Management Team

Board of Directors

Scientific and Medical Advisors

Intellectual Property

Management Team

Michael Lyle
Vice President, Research and Development

Dr. Michael Lyle was appointed as the Vice President of Research and Development in December 2009 after being the former Director of Chemistry at the company. In addition to leading the overall CMC program for the Company’s proprietary compounds, Dr. Lyle led two successful clinical trial applications related to the Company’s lead compound, WBI-1001, for the topical treatment of atopic dermatitis and psoriasis. Michael received his PhD in Chemistry at Simon Fraser University.